CAMBRIDGE, Mass. (AP) _ Akebia Therapeutics Inc. (AKBA) on Wednesday reported a loss of $34.1 million in its second quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 60 cents.

The kidney disease treatment developer posted revenue of $48.8 million in the period.

Akebia Therapeutics shares have fallen 35 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $9.72, a fall of 29 percent in the last 12 months.


This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on AKBA at